Insilico Medicine, a leading AI-driven pharmaceutical company backed by Qi Ming Venture Capital, successfully completed its IPO on the Hong Kong Stock Exchange, raising HKD 16.65 billion and positioning itself as a key player in the biotech landscape.

Target Information

Insilico Medicine, a global leader in AI-driven pharmaceuticals, successfully went public on the Hong Kong Stock Exchange on December 30, 2025. The IPO is noted as the largest biotech IPO in the Hong Kong market for 2025. The company offered shares at an initial price of HKD 24.05, with a first-day trading price of HKD 35.00, leading to a market capitalization of HKD 19.51 billion. Qi Ming Venture Capital was a significant financial backer, holding approximately 7% of the company's shares prior to the IPO.

Founded and led by Dr. Alex Zhavoronkov, Insilico Medicine is dedicated to extending human health spans through innovative AI solutions across various phases of drug development, from target discovery to molecular generation and clinical trials. The public offering is expected to enhance the resources available to further this mission, providing a framework for extending investment into innovative projects that can deliver globally differentiated therapeutic solutions to patients.

Industry Overview

In recent years, the biotech industry in Hong Kong has witnessed a significant transformation, propelled by advancements in technology and increasing investment from various stakeholders, including government entities and private funds. Hong Kong's strat